Biologics

Eleven potential blockbuster drugs offer hope, threaten budgets

Crowned by a potential cure for severe hemophilia A, which could become the most expensive drug ever, a new list of 11 medicines expected to generate $1 billion-plus in annual sales by the end of 2024 or earlier throws into stark relief the growing tension between medical innovation and society’s ability to pay for it. […]

India: The emerging hub for biologics and biosimilars

The global pharmaceutical industry is facing a shift from chemical-based drugs to biologics and biosimilars. While small molecule therapeutics had previously dominated research and captured major market share, the advent of large molecule therapeutics (biologics and biosimilars) has rapidly transformed the pharmaceutical industry. Given their targeted mechanism of action and reduced toxicity, biologics have gained […]

Accelerating – and maintaining – drug approvals in the U.S.

Bringing a drug to market is the ultimate milestone for any pharmaceutical firm that has invested significant effort, not to mention time and resources, into developing its product. But all that work and outlay does not stop at marketing approval—this achievement must be maintained. There can be various regulatory requirements that a firm must meet […]